Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Inclusion Criteria

• •1. All subjects must personally sign and date the consent form before initiating any study specific procedures or activities;
• •2. All subjects must be able to comply with all the scheduled procedures in the study;
• •3. Refractory or relapsed malignant Non-Hodgkin lymphoma, defined as one or more of the following: Relapsed in 6 months after most recent therapy; Progressive disease in standard chemotherapy; Disease progression or relapsed in ≤12 months of ASCT;
• •4. At least one measurable lesion per revised IWG Response Criteria;
• •5. Aged \<70 years;
• •6. Expected survival ≥12 weeks; Eastern cooperative oncology group (ECOG) performance status of≤2;
• •7. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks;
• •8. All other treatment induced adverse events must have been resolved to ≤grade 1;
• •9. Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB\>70g/L, Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN, Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome);